Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Presents FDA New Data Confirming No Link between Victoza and Cancer-Reuters


Friday, 14 Jun 2013 01:00am EDT 

Reuters reported that Novo Nordisk A/S is to present to U.S. Food and Drug Administration (FDA) new data confirming that the Company's GLP-1-analogue, Victoza, cannot be linked to cancer. The action has been taken to deny any suggestions that Victoza can lead to pancreatic cancer. 

Company Quote

261.1
2.9 +1.12%
5:35am EDT